Published in Drug Metabol Drug Interact on January 01, 2014
Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms. Drugs R D (2016) 0.80
Molecular expression and functional activity of vitamin C specific transport system (SVCT2) in human breast cancer cells. Int J Pharm (2014) 0.77
Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat. J Cent Nerv Syst Dis (2017) 0.75
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch (2003) 3.33
Impact of OATP transporters on pharmacokinetics. Br J Pharmacol (2009) 2.97
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther (2007) 2.91
The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta (2003) 2.53
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab (2009) 2.17
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem (2000) 1.85
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther (2004) 1.68
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci (2006) 1.52
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Pharmacokinetic variability of anticancer agents. Nat Rev Cancer (2005) 1.29
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1.29
Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest (2003) 1.28
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer (2010) 1.25
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos (2013) 1.23
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 1.23
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem (2012) 1.18
Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci (2007) 1.11
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia (2007) 1.07
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant (2001) 1.04
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer (2014) 0.99
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res (2013) 0.97
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev (2012) 0.97
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics (2010) 0.96
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 0.96
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm (2012) 0.96
Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol (2013) 0.96
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist (2010) 0.95
Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther (2001) 0.94
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab Rev (2010) 0.93
Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res (1996) 0.91
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos (2013) 0.89
Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet (2011) 0.89
Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica (2007) 0.87
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int J Pharm (2012) 0.85
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol (2010) 0.83
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. Drug Metabol Drug Interact (2014) 0.82
Ocular drug delivery. AAPS J (2010) 2.19
Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells. Int J Pharm (2012) 2.07
Recent perspectives in ocular drug delivery. Pharm Res (2008) 1.72
MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol (2006) 1.40
Novel approaches to retinal drug delivery. Expert Opin Drug Deliv (2007) 1.26
Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest Ophthalmol Vis Sci (2003) 1.21
Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther (2003) 1.18
Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther (2005) 1.17
MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci (2006) 1.15
Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. J Pharmacol Exp Ther (2004) 1.13
Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech (2003) 1.12
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm (2007) 1.10
Mitochondrial dysfunction in retinal diseases. Curr Eye Res (2011) 1.08
Identification of a Na+-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol Pharm (2005) 1.04
Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci (2010) 1.04
Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther (2004) 1.03
Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets (2013) 1.01
Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm (2013) 1.01
Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr Eye Res (2004) 1.01
Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res (2008) 1.01
Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm (2010) 1.01
Role of efflux pumps and metabolising enzymes in drug delivery. Expert Opin Drug Deliv (2005) 1.00
Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. Int J Pharm (2008) 1.00
Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res (2009) 1.00
Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm (2006) 1.00
Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea. J Ocul Pharmacol Ther (2006) 1.00
In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci (2003) 1.00
Identification and functional characterization of a Na+-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest Ophthalmol Vis Sci (2003) 0.99
Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm Res (2002) 0.99
Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids--quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal (2010) 0.99
Development of a novel formulation containing poly(d,l-lactide-co-glycolide) microspheres dispersed in PLGA-PEG-PLGA gel for sustained delivery of ganciclovir. J Control Release (2005) 0.98
Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev (2004) 0.98
Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J Pharmacol Exp Ther (2003) 0.98
Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization. Mol Pharm (2005) 0.98
In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther (2004) 0.97
Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J Pharm Sci (2002) 0.97
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int J Pharm (2007) 0.96
Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea. J Ocul Pharmacol Ther (2009) 0.96
Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm (2012) 0.96
Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des (2013) 0.95
Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther (2007) 0.95
Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int J Pharm (2005) 0.95
Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents. Recent Pat Antiinfect Drug Discov (2012) 0.94
Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int J Pharm (2008) 0.94
Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm (2005) 0.94
A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers. J Neuroimmune Pharmacol (2011) 0.94
Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol Pharm (2006) 0.93
Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J Ocul Pharmacol Ther (2006) 0.93
Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir. Biochem Biophys Res Commun (2010) 0.93
Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv (2011) 0.92
Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp Eye Res (2006) 0.92
Microvascular complications and diabetic retinopathy: recent advances and future implications. Future Med Chem (2013) 0.92
Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J Ocul Pharmacol Ther (2006) 0.92
Effect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells. J Ocul Pharmacol Ther (2011) 0.91
Long-term delivery of protein therapeutics. Expert Opin Drug Deliv (2014) 0.91
Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther (2002) 0.91
Novel strategies for anterior segment ocular drug delivery. J Ocul Pharmacol Ther (2012) 0.91
Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J Ocul Pharmacol Ther (2007) 0.90
Mechanism of L-ascorbic acid uptake by rabbit corneal epithelial cells: evidence for the involvement of sodium-dependent vitamin C transporter 2. Curr Eye Res (2006) 0.90
Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. J Ocul Pharmacol Ther (2009) 0.90
Effect of polymer blending on the release of ganciclovir from PLGA microspheres. Pharm Res (2006) 0.90
Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int J Pharm (2003) 0.90
Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am J Ther (2004) 0.90
Nanomicellar Topical Aqueous Drop Formulation of Rapamycin for Back-of-the-Eye Delivery. AAPS PharmSciTech (2014) 0.90
Folic acid transport via high affinity carrier-mediated system in human retinoblastoma cells. Int J Pharm (2007) 0.89
Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Int J Pharm (2008) 0.89
Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina. J Ocul Pharmacol Ther (2009) 0.89
Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies. Int J Pharm (2006) 0.89
An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes. Drug Alcohol Depend (2012) 0.89
Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Mol Pharm (2010) 0.89